The case for using 5-aminosalicyclates in Crohn's disease: Pro

Stephen B. Hanauer

doi:10.1097/01.MIB.0000160743.24772.69

The case for using 5-aminosalicyclates in Crohn's disease: Pro

Stephen B. Hanauer^*

^*Corresponding author for this work

Medicine, Gastroenterology Division

Research output: Contribution to journal › Review article › peer-review

17 Scopus citations

Abstract

Mesalamine has a well-established role in the management of ulcerative colitis. However, its role in the management of Crohn's disease (CD) is less clear. Studies evaluating its therapeutic value in CD have produced both positive and negative results. Meta-analyses have not clarified the situation, possibly because they have combined studies of different design. This debate critically examines the evidence for and against the use of mesalamine in CD.

Original language	English (US)
Pages (from-to)	609-612
Number of pages	4
Journal	Inflammatory bowel diseases
Volume	11
Issue number	6
DOIs	https://doi.org/10.1097/01.MIB.0000160743.24772.69
State	Published - Jun 2005

ASJC Scopus subject areas

Gastroenterology
Immunology and Allergy

Access to Document

10.1097/01.MIB.0000160743.24772.69

Cite this

@article{deab814389724e4bb00842caa4e2e9b9,

title = "The case for using 5-aminosalicyclates in Crohn's disease: Pro",

abstract = "Mesalamine has a well-established role in the management of ulcerative colitis. However, its role in the management of Crohn's disease (CD) is less clear. Studies evaluating its therapeutic value in CD have produced both positive and negative results. Meta-analyses have not clarified the situation, possibly because they have combined studies of different design. This debate critically examines the evidence for and against the use of mesalamine in CD.",

author = "Hanauer, {Stephen B.}",

year = "2005",

month = jun,

doi = "10.1097/01.MIB.0000160743.24772.69",

language = "English (US)",

volume = "11",

pages = "609--612",

journal = "Inflammatory bowel diseases",

issn = "1078-0998",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - The case for using 5-aminosalicyclates in Crohn's disease

T2 - Pro

AU - Hanauer, Stephen B.

PY - 2005/6

Y1 - 2005/6

N2 - Mesalamine has a well-established role in the management of ulcerative colitis. However, its role in the management of Crohn's disease (CD) is less clear. Studies evaluating its therapeutic value in CD have produced both positive and negative results. Meta-analyses have not clarified the situation, possibly because they have combined studies of different design. This debate critically examines the evidence for and against the use of mesalamine in CD.

AB - Mesalamine has a well-established role in the management of ulcerative colitis. However, its role in the management of Crohn's disease (CD) is less clear. Studies evaluating its therapeutic value in CD have produced both positive and negative results. Meta-analyses have not clarified the situation, possibly because they have combined studies of different design. This debate critically examines the evidence for and against the use of mesalamine in CD.

UR - http://www.scopus.com/inward/record.url?scp=20444466001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444466001&partnerID=8YFLogxK

U2 - 10.1097/01.MIB.0000160743.24772.69

DO - 10.1097/01.MIB.0000160743.24772.69

M3 - Review article

C2 - 15905710

AN - SCOPUS:20444466001

SN - 1078-0998

VL - 11

SP - 609

EP - 612

JO - Inflammatory bowel diseases

JF - Inflammatory bowel diseases

IS - 6

ER -

The case for using 5-aminosalicyclates in Crohn's disease: Pro

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this